# Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

> **NCT00924287** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT00924287
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** This study was terminated after the first patient treated on study died as a result of the treatment.
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924287, "Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00924287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*